Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.

May 16, 2025

Vol.51 No.19

By Jacquelyn Cobb and Claire Marie Porter

Guest Editorial

An opportunity for Trump: Position U.S. cancer science to lead the world

Last November, the American public voted on America First causes, which include the greatest scientific discovery and achievement enterprise in the world: The National Institutes of Health. NIH has made America first in biomedical science for the past century.

Senate Democratic minority report: Trump cuts cancer research by 31%

Before two consecutive congressional hearings on the Trump administration’s “skinny budget” proposal on May 14, Sen. Bernie Sanders (I-VT), ranking member of the Senate Health, Education, Labor, and Pensions Committee, released a report assessing the administration’s impact on biomedical research.

May 16, 2025

Vol.51 No.19

By Claire Marie Porter

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

How is the enterprise of cancer research doing after the first 100 days of the Trump administration?

May 09, 2025

Vol.51 No.18

By Paul Goldberg and Jacquelyn Cobb

Guest Editorial

George Weiner: Cancer centers are special, as are site visits in CCSG review

The cancer center program of the NCI is a success that is admired not only within the NIH but worldwide. This is due, in large part, to the cancer center review process that has evolved and strengthened over the years.

May 09, 2025

Vol.51 No.18

By George J. Weiner

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced

NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

An opportunity for Trump: Position U.S. cancer science to lead the world

Senate Democratic minority report: Trump cuts cancer research by 31%

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

George Weiner: Cancer centers are special, as are site visits in CCSG review

Renew today!

Subscriber content

Never miss an issue!

Login

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced

NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFsTo avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

An opportunity for Trump: Position U.S. cancer science to lead the world

Senate Democratic minority report: Trump cuts cancer research by 31%

Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit

George Weiner: Cancer centers are special, as are site visits in CCSG review

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit